Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 6;18(1):975.
doi: 10.1186/s12889-018-5806-x.

The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review

Affiliations

The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review

Adrian Gheorghe et al. BMC Public Health. .

Abstract

Background: The evidence on the economic burden of cardiovascular disease (CVD) in low- and middle- income countries (LMICs) remains scarce. We conducted a comprehensive systematic review to establish the magnitude and knowledge gaps in relation to the economic burden of CVD and hypertension on households, health systems and the society.

Methods: We included studies using primary or secondary data to produce original economic estimates of the impact of CVD. We searched sixteen electronic databases from 1990 onwards without language restrictions. We appraised the quality of included studies using a seven-question assessment tool.

Results: Eighty-three studies met the inclusion criteria, most of which were single centre retrospective cost studies conducted in secondary care settings. Studies in China, Brazil, India and Mexico contributed together 50% of the total number of economic estimates identified. The quality of the included studies was generally low. Reporting transparency, particularly for cost data sources and results, was poor. The costs per episode for hypertension and generic CVD were fairly homogeneous across studies; ranging between $500 and $1500. In contrast, for coronary heart disease (CHD) and stroke cost estimates were generally higher and more heterogeneous, with several estimates in excess of $5000 per episode. The economic perspective and scope of the study appeared to impact cost estimates for hypertension and generic CVD considerably less than estimates for stroke and CHD. Most studies reported monthly costs for hypertension treatment around $22. Average monthly treatment costs for stroke and CHD ranged between $300 and $1000, however variability across estimates was high. In most LMICs both the annual cost of care and the cost of an acute episode exceed many times the total health expenditure per capita.

Conclusions: The existing evidence on the economic burden of CVD in LMICs does not appear aligned with policy priorities in terms of research volume, pathologies studied and methodological quality. Not only is more economic research needed to fill the existing gaps, but research quality needs to be drastically improved. More broadly, national-level studies with appropriate sample sizes and adequate incorporation of indirect costs need to replace small-scale, institutional, retrospective cost studies.

Keywords: Cardiovascular disease; Economic burden; Hypertension; Low-income; Middle-income; Non-communicable disease; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Not applicable.

Not applicable.

The author(s) declare that they have no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
PRISMA flowchart
Fig. 2
Fig. 2
Direct medical costs (Int$ 2014) per episode by CVD category (n = 42 studies). 1) For each CVD category and economic perspective (Panel a) or study scope (Panel b), the boxplot represents cost estimates from individual studies (circles), the sub-group median (vertical line in solid box), inter-quartile range IQR (distance between lower and upper hinges, which correspond to the first and third quartile) and the upper (lower) whisker extends from the hinge to the largest (lowest) observed value no further than 1.5 * IQR from the hinge; 2) Three cost estimates ranging between Int$42,000 and Int$67,000, for very complex interventions in coronary acute syndrome patients (Moleregpoom et al., 2007; Thailand), were excluded from this Figure for ease of visualization. The median cost estimated in the same study for the simplest coronary acute syndrome cases is represented
Fig. 3
Fig. 3
Monthly direct medical costs (Int$ 2014) by CVD category (n = 31 studies). For each CVD category and economic perspective (Panel a) or study scope (Panel b), the boxplot represents cost estimates from individual studies (circles), the sub-group median (vertical line in solid box), inter-quartile range IQR (distance between lower and upper hinges, which correspond to the first and third quartile) and the upper (lower) whisker extends from the hinge to the largest (lowest) observed value no further than 1.5 * IQR from the hinge

Similar articles

Cited by

References

    1. Vos T, et al., Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the global burden of disease study 2016. The Lancet. 2017;390(10100):1211–1259. - PMC - PubMed
    1. Hay SI, et al., Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: A systematic analysis for the global burden of disease study 2016. 2017. The Lancet. 2017;390(10100):1260–1344. - PMC - PubMed
    1. Naghavi M, et al., Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the global burden of disease study 2016. 2017. The Lancet. 2017;390(10100):1151–1210. - PMC - PubMed
    1. Alwan A, MacLean DR. A review of non-communicable disease in low- and middle-income countries. International Health. 2009;1(1):3–9. doi: 10.1016/j.inhe.2009.02.003. - DOI - PubMed
    1. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the global burden of disease study 2013. The Lancet. 2014;385(9963):117–171. - PMC - PubMed

Publication types